Pro-Med

Pro-Med focuses on developing innovative drug delivery systems, particularly the SmartDose® On-Body Delivery System, facilitating efficient self-administration of medications for patients. Founded in 1997 in Linz, Austria, Pro-Med specializes in drug delivery solutions. The founder, Enrico Armiento, has a history of innovation in healthcare technology. The company raised EUR 3 million in a Series B funding round in June 2004 from GCP Gamma Capital Partners and Sofinnova Partners, marking its second deal.

Pro-Med specializes in the SmartDose® On-Body Delivery System, launched in 2010. This system enables self-administration of medications, particularly for biologics, featuring advanced technologies for precise dosing and improved patient compliance. Pro-Med serves pharmaceutical and biotechnology companies, healthcare providers, and patients globally, particularly in North America, Europe, and select Asia-Pacific regions. Pro-Med generates revenue primarily through B2B contracts with pharmaceutical and biotech firms.

Its revenue model includes long-term contracts for the supply of SmartDose® technology and related services, focusing on both one-time sales and ongoing service agreements, reflecting the necessity for continued support in drug delivery. Pro-Med aims to leverage the recent EUR 3 million raised in June 2004 to enhance its product offerings and expand its market presence. The company is working on the next generation of the SmartDose® system, with plans to enter new geographic markets by 2025, specifically targeting regions within Europe and Asia to broaden access to its innovative drug delivery solutions.